Skip to main content

New story in Health from Time: How Artificial Intelligence Can Help Pick the Best Depression Treatments for You



Seeking out help for depression is hard enough. It doesn’t make things any easier that it can take weeks, months or longer of trying different treatments to find something that works. Doctors typically start patients on antidepressants, but they take at least four weeks to start working, and research has shown that only about 30% respond well to the first drug they’re prescribed. “Right now, treatment selection is purely based on trial and error,” says Dr. Madhukar Trivedi, a professor of psychiatry at the University of Texas Southwestern Medical Center.

But promising new research published in February in Nature Biotechnology suggests that a simple brain test, paired with insights from artificial intelligence (AI), can predict whether an antidepressant will work on a given patient. Trivedi and a team of researchers took data from a previous study in which more than 200 people with depression had an electroencephalogram (EEG)—a non-invasive test that records a person’s brain waves through electrodes placed on their scalp—and were then given either sertraline (a widely prescribed antidepressant marketed as Zoloft) or a placebo for eight weeks. If those who responded well to sertraline shared a common brain-wave pattern, that might provide a big clue for whether or not any individual will respond to the drug.

Trivedi and the team created a machine learning algorithm designed to analyze the EEG data, and it found that 65% of the study participants with a particular brainwave signature also showed a strong response to sertraline. This, says Dr. Amit Etkin, one of the paper’s authors and a professor of psychiatry and behavioral sciences at Stanford University, is “far better” than using clinical factors, like whether patients have certain kinds of symptoms, to try to guess whether they will respond well to a drug.

The researchers also applied their AI algorithm to data from a separate study in which people had EEG testing before undergoing transcranial magnetic stimulation (TMS), a brain-stimulation technique to treat depression. They found that people who were not expected to respond well to sertraline, based on their brain waves, tended to have positive responses to TMS.

All of this research is still preliminary. But the use of AI in psychiatry is expanding quickly. AI is powering a broad range of applications in use or in development to diagnose or treat mental illness; therapy apps and chatbots use machine learning to tailor advice to users, for example, and a study in 2018 used AI to analyze the words people post on Facebook and found that an algorithm could pretty accurately predict whether a person gets a depression diagnosis later on. Computer analysis of EEG data is also growing. Researchers have recently used algorithms to mine EEG data of infants and were able to predict autism diagnoses in children just a few months old.

“These are exciting results,” says Michele Ferrante, computational-psychiatry program director at the National Institute of Mental Health (which funded the team’s research). “This EEG lab test is quick”—it takes just a few minutes—”cost-effective, and its outcome is of high-clinical impact.” The next step is to conduct clinical trials in which AI suggests a treatment based on the patient’s EEG patterns “to see if these results hold true.” Etkin believes that in about five years, his team’s prediction tool will be ready for clinical usage.

As a more personalized approach to depression emerges, thanks to AI, Trivedi hopes that people will be more inclined to seek treatment and stick with it. “It gives patients a lot more confidence in the treatments that they are being provided,” he says. “That improves their ability to stay with that treatment until they get better. We are not shooting in the dark.”

Popular posts from this blog

New story in Health from Time: COVID-19 Has Been ‘Apocalyptic’ for Public Transit. Will Congress Offer More Help?

While trying to get to work over the past few months, Brittany Williams, a Seattle home care worker, has often been passed by two or three buses before one stops to let her board. Buses in her area that once carried anywhere from about 50 to 100 passengers have been limited to between 12 and 18 to prevent overcrowding in response to coronavirus, and Williams’ commute, typically a half-hour ride, now takes more than double that time. Other Seattle transit riders have described budgeting as much as an extra hour per trip to account for the reduced capacity, eating into their time at work, school or with family. Even with the ridership limits in place, Williams, 34, doesn’t feel safe on public transit. Some passengers don’t wear face coverings, and bus drivers sometimes ignore capacity limits, she says. On one ride with her seven-year-old son, she decided to get off at a stop far from her home after a driver allowed a crowd of people to board. “It’s very trying. I’ll put...

New story in Health from Time: An At-Home Coronavirus Test May Be On the Way in the U.S.

As cases of COVID-19 continue to climb in the U.S. , there’s a new urgency to make sure there are as many tests as possible to diagnose people who have symptoms that might indicate an infection. Knowing if people are positive is important for guiding their next steps: self-isolation, avoiding contact with others, and, if their symptoms get worse, seeking medical care. To date, access to tests has been spotty at best across the country, and while more kits are now available than even a week ago , most are gene-based assays that take several days for commercial labs to process and produce results. That may change in about two months if the Food and Drug Administration (FDA) gives Emergency Use Authorization to the first blood-based COVID-19 test in the U.S. Scanwell Health, an at-home test company based in California, licensed the rights to a test developed by Chinese company Innovita, which was used extensively at the height of country’s epidemic earlier this year. “The ...

New story in Health from Time: A Montana Care Home Refused Free COVID-19 Tests. Now, Nearly Every Resident Has Coronavirus

(BILLINGS, Mont.) — It was meant to be a last line of defense to protect the most vulnerable as the coronavirus spread across the United States : Montana officials offered free testing in May for staff and residents at assisted living and long-term care facilities. But not all of them followed through, according to state data, including a facility in Billings, Montana’s largest city, that cares for people with dementia and other memory problems. The virus has infected almost every resident and killed eight, accounting for almost a quarter of Montana’s 34 confirmed deaths. Thirty-six employees also have tested positive at the facility where 59 people lived before the deaths began. Read more: ‘It’s Getting Worse.’ Nursing Home Workers Confront Risks in Facilities Devastated by Coronavirus While Montana’s rates of confirmed infections and deaths are much lower than other parts of the country, the outbreak at Canyon Creek Memory Care illustrates that even the most simple an...